Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05112536
Title Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors G1 Therapeutics, Inc.
Indications

triple-receptor negative breast cancer

Therapies

Cyclophosphamide + Doxorubicin + Pembrolizumab + Trilaciclib

Carboplatin + Paclitaxel + Trilaciclib

Trilaciclib

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Cancer and Blood Specialty Clinic Los Alamitos California 90720 United States Details
UCLA Department of Medicine - Hematology/Oncology Santa Monica California 90404 United States Details
PIH Health Whittier California 90602 United States Details
Nebraska Hematology-Oncology, P.C. Lincoln Nebraska 68506 United States Details
Duke University Medical Center Durham North Carolina 27710 United States Details
Texas Oncology - Baylor Charles A. Sammons Cancer Center Dallas Texas 75246 United States Details
Virginia Oncology Associates Norfolk Virginia 23502 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field